Pharmaceutisch Weekblad

, Volume 5, Issue 5, pp 197–204 | Cite as

Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs

  • P. A. van Zwieten
  • A. de Jonge
  • P. B. M. W. M. Timmermans
Review Articles


Inhibitors of the angiotensin I converting enzyme (captopril, enalapril) offer a new principle in the drug treatment of hypertension and congestive heart failure. The present survey deals with the mode of action of the converting enzyme inhibitors, including possible interference with the renin-angiotensin systems in the kidney, the vascular wall and the brain, with the kallikreine-bradykinine system and with the sympathetic nervous system, at both pre- and postjunctional sites. Furthermore, the haemodynamic pattern as well as the therapeutic applications are discussed, including the most important sideeffects, contra-indications, interactions and clinical pharmacokinetic properties.


Hypertension Heart Failure Nervous System Angiotensin Congestive Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adigun, S.A., D.P. Cloug andR. Hatton (1980)Clin. Sci. 58, 549–554.PubMedGoogle Scholar
  2. Antonaccio, M.J., andL. Kerwin (1981)Hypertension 3, suppl. 1, 54–62.Google Scholar
  3. Asaad, M.M., andM.J. Antonaccio (1982)Hypertension 4, 487–493.PubMedGoogle Scholar
  4. Atkinson, A.B., andJ.L.S. Robertson (1979)Lancet 2, 836–839.PubMedGoogle Scholar
  5. Atlas, S.A., D.B. Case, J.E. Sealey et al. (1979)Hypertension 1, 274–280.PubMedGoogle Scholar
  6. Birkenhäger, W.H., andM.A.D.H. Schalekamp (1976)Control mechanisms in essential hypertension. Elsevier/ North Holland Biomedical Press, Amsterdam, 15–41.Google Scholar
  7. Campbell, B.C., A.M. Shepherd, H.L. Elliott, K. Mclean andJ.L. Reid (1982)Brit. J. Clin. Pharmacol. 13, 755–757.Google Scholar
  8. Captopril Collaborative Study Group (1982)Lancet 1, 988–990.Google Scholar
  9. Cohen, M.L., andK.D. Kurt (1982)J. Pharmacol. Exp. Ther. 220, 63–69.PubMedGoogle Scholar
  10. Davis, J.O., andR.H. Freeman (1982)Am. J. Cardiol. 49, 1385–1389.PubMedGoogle Scholar
  11. De Jonge, A., B. Wilffert, H.O. Kalkman, J.C.A. Van Meel, M.J.M.C. Thoolen, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1981)Eur. J. Pharmacol. 74, 385–386.PubMedGoogle Scholar
  12. de Jonge, A., J.Th.A. Knape, J.C.A. van Meel, H.O. Kalkman, B. Wilffert, M.J.M.C. Thoolen, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1982)Naunyn-Schmiedeberg's Arch. Pharmacol. 321, 309–313.CrossRefGoogle Scholar
  13. de Jonge, A., J.Th.A. Knape, J.C.A. van Meel, H.O. Kalkman, B. Wilffert, M.J.M.C. Thoolen, P. Van Brummelen, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1983)Eur. J. Pharmacol. 88, 231–240.PubMedGoogle Scholar
  14. De Jonge, A., M.J.M.C. Thoolen, P.B.M.W.M. Timmermans andP.A. Van Zwieten (1984)Progress in Pharmacology, in press.Google Scholar
  15. Duchin, K.L., S.M. Singhvi, D.A. Willard, B.H. Migdalof, andD.N. Mckinstry (1982)Clin. Pharmacol. Ther. 31, 452–458.PubMedGoogle Scholar
  16. Dzau, V.J., andK.E. Sands (1982)Clin. Sci. 63, 163S-166S.Google Scholar
  17. Erdös, E.G. (1975)Circulation Res. 36, 247–255.PubMedGoogle Scholar
  18. Ferguson, R.K., G.A. Turini, H.R. Brunner andH. Gavras (1977)Lancet II, 775.Google Scholar
  19. Ferguson, R.K., andP.H. Vlasses (1981)Am. Heart J. 101, 650–655.CrossRefPubMedGoogle Scholar
  20. Ferguson, R.K., P.H. Vlasses, B.N. Swanson, P. Mojaveria, M. Hichens, J.D. Irvin andP.B. Huber (1982)Clin. Pharmacol. Ther. 32, 452–457.Google Scholar
  21. Ganten, D., Th. Unger, R. Rockhold, K. Schaz andG. Speck (1979) In:Radioimmunoassay of drugs and hormones in cardiovascular medicine (Albertini, A., M. Da Prada, B. Peskar, Eds.). Elsevier, Amsterdam, 33.Google Scholar
  22. Garst, J.B., S. Koletsky, P.E. Wisenbaugh, M. Hadady andD. Matthews (1979)Clin. Sci. 56, 41–46.PubMedGoogle Scholar
  23. Gavras, H., H.R. Brunner, G.A. Turini, G.R. Kershaw, G.P. Tifft, S. Cuttelod, I. Gavras, R.A. Vukovich andD.N. Mckinstry (1978)N. Engl. J. Med. 298, 991.PubMedGoogle Scholar
  24. Hatton, R., andD.P. Clough (1982)J. Cardiovasc. Pharmacol. 4, 116–123.PubMedGoogle Scholar
  25. Imai, Y., K. Abe, M. Sato, T. Haruyame, M. Hiwatari, T. Goto, K. Sato, Y. Kasai, J. Tajima andK. Yoshinaga (1982)Am. Heart J. 104, 1339–1345.CrossRefPubMedGoogle Scholar
  26. Kiowski, W., P. Van Brummelen, L. Hulthen, F.W. Amann andF.R. Bühler (1982)Clin. Pharmacol. Ther. 31, 677–682.PubMedGoogle Scholar
  27. Knape, J.Th.A., A. De Jonge, P.B.M.W.M. Timmermans AndP.A. Van Zwieten (1982)Pharm. Weekbl. [Sci.] 4, 163.Google Scholar
  28. Knape, J.Th.a. (1983)Naunyn-Schmiedeberg's Arch. Pharmacol. 322, (suppl.) R 21.Google Scholar
  29. Kripalani, K.J., D.N. Mckinstry, S.M. Singhvi, D.A. Willard, R.A. Vukovich andB.H. Migdalof (1980)Clin. Pharmacol. Ther. 27, 636–641.PubMedGoogle Scholar
  30. Leier, C.V., D. Bambach, S. Nelson, J.B. Hermiller, P. Huss, R.D. Magorien andD.V. Unverferth (1983)Circulation 67, 155–160.PubMedGoogle Scholar
  31. Lund-Johansen, P. (1972) In:Hypertension: Mechanisms and Management (Onesti, G., K.E. Kim andJ.H. Moyer, Eds.). Grune & Stratton, New York, 43.Google Scholar
  32. Macgregor, G.A., M.D. Markandur, R.A. Banks, J. Bayliss, J.E. Roulston andJ.C. Jones (1982)Brit. Med. J. 284, 693–697.Google Scholar
  33. Macgregor, G.A., M.D. Markandur, J.E. Roulston, J.C. Jones andJ.J. Morton (1981)Nature 291, 329–331.CrossRefPubMedGoogle Scholar
  34. Man In 'T Veld, A.J., I.M. Schicht andF.H.M. Derkx et al. (1980)Brit. Med. J. 281, 288–290.Google Scholar
  35. Millar, J.A., F.H.M. Derkx, K. McLean andJ.L. Reid (1982)Brit. J. Clin. Pharmacol. 14, 347–355.Google Scholar
  36. Mimran, A., andR. Targhetta (1979)New Engl. J. Med. 301, 1289–1290.PubMedGoogle Scholar
  37. Mookherjee, S., G.H. Anderson, R. Eich, N. Hill, H. Smylyan, D.H.P. Streeten, S. Vardan andR. Warner (1983)Am. Heart J. 105, 106–111.CrossRefPubMedGoogle Scholar
  38. Niarchos, A.P., H.H. Whitman, J.E. Goldstein andJ.H. Laragh (1982)Am. Heart J. 104, 843–838.CrossRefGoogle Scholar
  39. Peach, M.J. (1977)Physiol. Rev. 57, 313–341.PubMedGoogle Scholar
  40. Philips, M.I., J. Weyenheimer, D. Felix, D. Ganten andW. Hofman (1979)Fed. Proc. 38, 53.Google Scholar
  41. Romankiewicz, J.A., R.N. Brogden, R.C. Heel, T.M. Speight andG.S. Avery (1983)Drugs 25, 6–40.PubMedGoogle Scholar
  42. Schalekamp, M.A.D.H., andP.A. Van Zwieten (1983)Remming van angiotensine I converting enzyme (ACE) ter behandeling van hoge bloeddruk en hartfalen. In:Het Medisch Jaar 1983 (Van Es, J.C., J.V. Joossens, E. Mandema andG. Olthuis, Eds.). Bohn, Scheltema & Holkema, Utrecht, 1–22.Google Scholar
  43. Soudijn, W. (1982)Pharm. Weekbl. [Sci.] 4, 154–158.Google Scholar
  44. Stephen, S.L., L. Swartz andG.H. Williams (1982)Am. J. Cardiol. 49, 1405–1409.Google Scholar
  45. Streeten, D.H.P., L.P. Kerr andC.B. Kerr et al. (1972)Lancet 2, 1048–1053.PubMedGoogle Scholar
  46. Sturani, A., C. Chiarini, E. Degli Esposti, A. Santoro, A. Zuccala andP. Zucchelli (1982)Brit. J. Clin. Pharmacol. 14, 849–855.Google Scholar
  47. Unger, Th., I. Kaufmann-Bühler, B. Schölkens andD. Ganten (1981)Eur. J. Pharmacol. 70, 467–478.CrossRefPubMedGoogle Scholar
  48. Unger, TH., T. Yukimura, M. Marin-Grez, R.E. Lang, W. Rascher andD. Ganten (1982)Eur. J. Pharmacol. 78, 411–420.CrossRefPubMedGoogle Scholar
  49. Ulm, E.H., M. Hichens, H.J. Gomez, A.E. Till, E. Hand, T.C. Vassil, J. Biollaz, H.R. Brunner andJ.L. Schelling (1982)Brit. J. Clin. Pharmacol. 14, 357–362.Google Scholar
  50. Vidt, D.G., E.L. Bravo andF.M. Foudd (1982)New Engl. J. Med. 306, 214–218.PubMedGoogle Scholar
  51. Westfall, T.C. (1977)Physiol. Rev. 57, 659.PubMedGoogle Scholar
  52. Witzgall, H., F. Hirsch, B. Scherer andP.C. Weber (1982)Clin. Sci. 62, 611–615.PubMedGoogle Scholar
  53. Zimmerman, B.C. (1981)Clin. Sci. 60, 343–348.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1983

Authors and Affiliations

  • P. A. van Zwieten
    • 1
  • A. de Jonge
    • 1
  • P. B. M. W. M. Timmermans
    • 1
  1. 1.Division of PharmacotherapyUniversity of AmsterdamTV AmsterdamThe Netherlands

Personalised recommendations